Table 2.

Inflammatory biomarker concentrations for exercisers and controls 6 and 12 months from baseline

Baseline6 months12 months
Geometric mean (95% CI)aGeometric mean (95% CI)Geometric mean (95% CI)Treatment effect ratio of exercise/control (95% CI)bBetween-group P
CRPa (mg/L)
 Exercisersc1.4 (1.2–1.6)1.2 (1.1–1.4)1.1 (1.0–1.3)0.87 (0.79–0.96)0.005
 Controlsd1.3 (1.1–1.5)1.3 (1.1–1.5)1.3 (1.1–1.5)
IL-6 (pg/mL)
 Exercisers1.5 (1.4–1.6)1.5 (1.4–1.6)1.5 (1.4–1.7)0.99 (0.92–1.07)0.785
 Controls1.6 (1.4–1.7)1.5 (1.4–1.7)1.6 (1.4–1.7)
TNF-α (pg/mL)
 Exercisers1.5 (1.4–1.6)1.5 (1.4–1.6)1.4 (1.3–1.5)1.00 (0.97–1.04)0.912
 Controls1.4 (1.4–1.5)1.4 (1.4–1.5)1.4 (1.3–1.4)
  • aTop 1% of CRP measures (10 of 938) were excluded from analyses; 3 controls and 1 exerciser were excluded.

  • bThe TER was calculated from a general linear model for each biomarker, estimating a parameter with anti-logarithm corresponding to the ratio of adjusted geometric means for the exercise intervention group over the control group; this ratio was assumed to be common at 6 months and 12 months postrandomization. A ratio less than 1.0 indicates lower inflammatory marker levels in exercisers relative to controls at 6 and 12 months; a ratio greater than 1.0 indicates a higher inflammatory marker levels in exercisers; and a ratio equal to 1.0 indicates no difference between exercisers and controls.

  • cExercise group: n, baseline = 160, 6 months = 154, 12 months = 154.

  • dControl group: n, baseline = 160, 6 months = 154, 12 months = 156.